N/A
Completed N=14
Effect of Formoterol on the Counterregulatory Hormonal Response to Hypoglycemia in Type 1 Diabetes.
Source: ClinicalTrials.gov NCT01194479 ↗Enrolled (actual)
14
Serious AEs
0.0%
Results posted
Mar 2016
Primary outcomePrimary: Glucagon (pg/mL) — 76; 74; 53; 56 pg/mL
Summary
Insulin treatment often causes the blood glucose levels to fall too low. The body usually responds to low blood glucose levels by releasing hormones which act against the insulin to help correct the low blood glucose levels. However, this hormone response can be altered in people with diabetes. Currently there are no therapeutic agents that can be used to improve the recovery from hypoglycemia (low blood sugar). The aim of this study is to determine whether a formoterol inhaler can be used to improve and accelerate the recovery from hypoglycemia in patients with type 1 diabetes.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Glucagon (pg/mL) |
76; 74; 53; 56; 59; 58 | — |
| PRIMARY Epinephrine (pg/mL) |
15; 16; 18; 17; 12; 12 | — |
| PRIMARY Norepinephrine (pg/mL) |
185; 192; 180; 133; 216; 273 | — |
| SECONDARY Blood Glucose Levels (Average) |
57.38; 58.39; 53.21; 55.43 | — |
Eligibility Criteria
Inclusion Criteria
- type 1 diabetes (well controlled, 2-3 hypoglycemic episodes/wk)
- age 18-50
- BMI 18-30
Exclusion Criteria
- pregnancy
- significant diabetes complications
- liver disease, cirrhosis
- cardiac disease
- neurological disorder
- autonomic neuropathy
- kidney disease
- lactose intolerance
Data sourced from ClinicalTrials.gov (NCT01194479). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.